Importance of detecting FLT3 and NPM1 gene mutations in acute myeloid leukemia - World Health Organization Classification 2008

Marley Aparecida Licínio1
Maria Cláudia Santos da Silva2

Acute myeloid leukemia is a group of malignancies characterized by uncontrolled proliferation of hematopoietic cells resulting from mutations that occur at different stages in the differentiation of myeloid precursor cells. In 2008, the World Health Organization (WHO-2008) published a new classification for cancers of the hematopoietic and lymphoid system. According to this classification, FLT3 and NPM1 gene mutations should be investigated for a more precise diagnosis and prognostic stratification of acute myeloid leukemia patients. It is well known that the presence of FLT3 gene mutations is considered an unfavorable prognostic factor and type-A NPM1 gene mutations are considered to be favorable. In developed countries, an analysis of FLT3 and NPM1 mutations is considered important for therapeutic decisions in acute myeloid leukemia patients. Hence, an analysis of FLT3 (internal tandem duplication - ITD- and D835 point mutation) and NPM1 gene mutations is extremely important as molecular markers for diagnosis, prognosis and monitoring of minimal residual disease in acute myeloid leukemia patients.

Keywords: Leukemia, myeloid, acute/genetics; Mutation; World Health Organization; Hematologic neoplasms/classification; Leukemia/classification

Introduction

Leukemias are a group of malignant neoplasms characterized by uncontrolled proliferation of hematopoietic cells in bone marrow and/or lymphoid tissues, which eventually reach the peripheral circulation and can infiltrate other organic systems.1 The uncontrolled proliferation of leukemic cells results from a clonal expansion of a single stem cell that has undergone a series of genetic alterations that accumulate in the single cell clone which has a proliferative advantage over other cells and prevents their differentiation. Due to this proliferation, leukemic cells inhibit the production of normal blood cells such as leukocytes, erythrocytes and platelets. Moreover, due to the functionality of the leukemic cells, affected individuals, besides suffering from anemia and bleeding disorders, are more susceptible to infections.2

Leukemic transformation may occur at different differentiation stages of lymphoid or myeloid precursors,
which characterizes this as a heterogeneous disease from
the biological and morphological points of view. As a
heterogeneous group of diseases, leukemias differ in etiology,
pathogenesis, prognosis and response to treatment.(3,4) The
fact that leukemia is a genetic disease makes the identification
of changes in blast cells essential to identify subgroups of
patients with distinct clinical features in order to guide
treatment, stratify prognosis and monitor therapeutic
response. (5)

Establishing an accurate diagnosis and clues as to
prognosis based on the analysis of clinical, biological, genetic
and molecular factors is one of the reasons for the therapeutic
success in patients with acute leukemia.(6,7) With recent
technological advances, new methodologies to diagnose
acute leukemia able to identify important prognostic factors
have emerged. Thus, in 2008, the World Health Organization
(WHO) established new criteria for the diagnosis of acute
leukemia (WHO-2008) which include the cell origin and
lineage, the maturation stage and type of cytogenetic or
molecular abnormalities involved in the pathogenesis of the
disease.(1,2)

Classification of acute myeloid leukemia
(WHO-2008)

The WHO-2008 classification established seven
subcategories for acute myeloid leukemia (AML): AML
associated with recurrent genetic abnormalities, AML with
myelodysplasia-related changes, myeloid neoplasms
associated with treatment, AML not classified in previous
items, myeloid sarcoma, myeloid-related proliferation with
Down syndrome and neoplasia of plasmacytoid dendritic
cells.(1,2)

Although some studies show that the cytogenetic
criteria are important for the stratification of prognosis as
favorable, intermediate and unfavorable,(3-5) others show that
only the evaluation of the karyotype is unsatisfactory for a
correct stratification of AML patients.(6,7) Moreover, it is
known that just chromosomal changes are insufficient for
the development of acute leukemia(1,2) and that about 45%
of AML patients have normal karyotypes.(6,7) Thus, it is
increasingly clear that the changes that disrupt genes
involved in the regulation of intracellular signal transduction
of cell death and proliferation act in collaboration with factors
resulting from chromosomal changes. Thus, the investigation
of possible changes is crucial for prognostic stratification,
which serves as a tool to predict the risk of relapse, resistance
to therapy and disease-free survival.(8)

Gilliland & Speck(9) suggest the following classification
for the mutations found in AML patients: those that confer
proliferative advantages and/or survival of hematopoietic
progenitors but do not affect differentiation (class I
mutations) and those that affect transcription or components
of the transcriptional complex and impair hematopoietic
differentiation (class II mutations). Thus, FLT3 gene
mutations cKIT and N-RAS belong to the class I
mutations(10-12) NPM1(13-15) and C/EBPa gene mutations and
AML1/ETO and abnormalities in CBFB/MYH11, PML/
RARA and MLL are class II mutations.(13-15)

The classification proposed by the WHO(1) in 2008,
suggests a new subtype, interim in nature, in the AML
subcategory associated with recurrent genetic
abnormalities: AML with NPM1 gene mutations. According
to the WHO, mutations of the FLT3 gene are associated to
more than one subtype, and, therefore, were not
classified as a distinct subtype, despite having clinical
importance.(1) Consequently, several research groups
emphasize that one should investigate FLT3 gene(1,14,17,18)
and NPM1 gene mutations,(1,14,17,19) in all AML patients as
they have clinical relevance that is crucial for correct
prognostic stratification.

It is known that FLT3 gene mutations are associated
with higher propensity for recurrence and shorter overall
disease-free survival and thus prognosis is unfavorable
(1,14,17,18) while the presence of NPM1 gene mutations confer a
favorable prognosis with greater disease-free survival for
AML patients.(14,22-24)

Importance of detecting NPM1 gene mutations for
the classification of acute myeloid leukemia
(WHO-2008)

The gene responsible for the synthesis of
nucleofosmine (NPM), also known as B23, NO38 or numatrin,
was mapped on chromosome 5q35 in humans. This gene
contains 12 exons that encode three isoforms of NPM: NPM1
(B23.1), NPM1.2 (B23.2) and NPM1.3 (B23.3). The NPM1
isoform is the most prevalent and has a C-terminal domain
and an N-terminal region.(25) The isoform NPM1.2 is a
truncated isoform found at very low levels in tissues and
isoform NPM1.3 has not been described much in the
literature. (26)

NPM1 is a nucleolar phosphoprotein which moves
between the nucleus and cytoplasm during the cell cycle
and interacts with several proteins. Because of this behavior,
NPM1 is a multifunctional protein, and is involved in the
processing of ribosomal RNA, centriole duplication, response
to stress stimuli such as UV irradiation and hypoxia,
maintenance of genomic stability by controlling cell ploidy,
participation in processes of DNA repair and transcription
regulation through the modulation of events of condensation
and decondensation of chromatin.(19,23,27) Moreover, NPM1
binds to p53 and regulates retinoblastoma (pRb)(28) the
p19ARF(29) and HDM2 proteins.(30)

Some studies have reported that NPM1 gene mutations
are found in about 35% of all AML patients and that these
are the most common molecular changes found in these
individuals.(19,31) These mutations are classified as A through
F according to the insertion or deletion of four base pairs in exon 12 of the C-terminal region (Figure 1), which makes a new nuclear export signal occur.\(^{(26,31)}\) NPM1 gene mutations, apart from being identified by the mutations found in the gene, can also be investigated by phenotypic changes investigating abnormalities in the NPM1 protein.\(^{(1,31)}\)

Many studies showed that NPM1 gene mutations were relevant only for patients with normal karyotypes.\(^{(17,24,31,32)}\) On the other hand, Haferlach et al.\(^{(33)}\) recently reported that, although AML patients with abnormal karyotypes represent a minority of individuals with NPM1 gene mutations, its definition, in respect to the biological, pathological and clinical characteristics, is very important. This study of Haferlach et al.\(^{(33)}\) was conducted with 631 AML patients who had NPM1 gene mutations; 14.7% of patients had abnormal karyotypes. However no differences were found in AML patients who had NPM1 mutations (normal or abnormal karyotypes) in respect to overall survival. This result confirms the concept that AML with NPM1 gene mutations should be clinically treated as a subtype, regardless of karyotype.\(^{(33)}\)

In the few studies with chromosomal abnormalities associated with NPM1 gene mutations in AML patients,\(^{(22,23)}\) the combination of biological and clinical importance has not been thoroughly investigated. Hence, during the preparation of the WHO-2008 classification, a point of debate was that the name of the subtype "AML with NPM1 gene mutations" was provisional and not definitive.

Falini et al.\(^{(42)}\) first described the ITD in the juxtamembrane region of one FLT3 allele in AML patients. The molecular model of the functioning of the altered protein has been described by in vitro studies that demonstrated uncontrolled dimerization of the juxtamembrane region caused by ITD, which loses its autoinhibitory ability and allows dimerization of the receptors independent of the ligand leading to autophosphorylation and autonomous growth of mutant cells.\(^{(43)}\) With the presence of ITD, autophosphorylation of the FLT3 receptor occurs, leading to permanent activation of this receptor, resulting in the activation of cell signaling pathways such as ERK and STAT5.\(^{(44)}\)

![Figure 1. Diagram of the NPM1 gene mutations. Adapted from Grisendi et al.\(^{(19)}\)](image)
The clinical significance of FLT3 mutations in AML was established from the correlation between the presence of ITD associated with leukocytosis, high percentages of blasts and unfavorable response to therapy. Some groups have also detected the presence of FLT3-ITD type mutations concomitant with other changes, for example, t(15;17), indicating a favorable prognosis, whereas the presence of t(6;9) is associated with unfavorable prognosis. However, the prognostic value of ITD in the FLT3 gene, associated with other changes, has not yet been well established, since there are published reports about ITD associated with high levels of relapse, with remission levels similar to a reference group without these mutations, or even associated with favorable clinical response.

FLT3 gene point mutations involve the activation loop of the second kinase domain, with the most common mutation resulting from the substitution of an aspartic acid residue at position 835 of exon 20 (formerly exon 17) for a tyrosine residue (D835). The activation loop is a common component of tyrosine-kinase receptors and its function is to block access of ATP and substrate to the kinase domain when the receptor is inactive. With a mutation in this region, the receptor is autoactivated and thus as in the presence of ITD, control of the signaling cascade promoted by FLT3 is lost, leading to cell proliferation.

The FLT3-D835 type mutation, also known as FLT3-TKD, was described in approximately 5%-10% of AML patients and has been correlated to an unfavorable prognosis. In the presence of two changes in FLT3, the low incidence (1.7%) reported makes an assessment of the clinical value difficult, however, the poor prognosis seems to prevail and in vitro studies suggest the development of resistance to conventional and specific therapies for the receptor.

In general, changes in FLT3, identified as a prognostic factor, have already been incorporated to determine risk and intensification of therapy in recently updated protocols in developed countries. While there is disagreement as to the aggressiveness of the disease, all studies reveal high white blood cell counts and lower remission rates with this mutation. Some studies have also assessed the possibility of using changes in FLT3 as tumor markers to identify minimal residual disease. The fact is that gains and losses of mutations have been observed during the course of treatment, which restricts the value of FLT3 as a marker indicative of relapse.

As already described in this article, AML patients with NPM1 gene mutations have a favorable prognosis, but if the patient has concomitant ITD for the FLT3 gene, the prognosis is considered unfavorable.

**Final considerations**

In the literature, some phase I and II, and phase III clinical trials investigated the benefits of the use of FLT3 inhibitors in patients with FLT3 gene mutations. These results show the importance of the investigation of FLT3 gene mutations for stratification of prognosis in AML, because the presence of these mutations will affect the choice of treatment. In addition, new studies involving the investigation of NPM1 gene mutations are extremely important because they can clarify the characterization of the subtype "AML with NPM1 gene mutations."

**Resumo**

As leucemias mieloides agudas (LMA) constituem um grupo de neoplasias malignas caracterizadas pela proliferação descontrolada de células hematopoéticas, decorrente de mutações que podem ocorrer em diferentes fases da diferenciação de células precursoras mieloides. Em 2008, a Organização Mundial da Saúde (OMS-2008) publicou uma nova classificação para neoplasias do sistema hematopoético e linfóide. De acordo com essa classificação, para um diagnóstico mais preciso e estratificação de prognóstico de pacientes com leucemias mieloides agudas, devem-se pesquisar mutações nos genes FLT3 e NPM1. Sabe-se que a presença de mutações no gene FLT3 é de prognóstico desfavorável e que as mutações no gene NPM1 do tipo A são de prognóstico favorável. Assim, nos países desenvolvidos, a análise das mutações no gene FLT3 e NPM1 tem sido considerada como um fator de prognóstico importante na decisão terapêutica em pacientes com diagnóstico de leucemias mieloides agudas. Considerando essas informações, é de extrema importância a análise das mutações no gene FLT3 (duplicação interna em tandem - DIT - e mutação pontual D835) e no gene NPM1 como marcadores moleculares para o diagnóstico, o prognóstico e a...
monitoração de doença residual mínima em pacientes com leucomias mieloides agudas.

Descritores: Leucemia mieloide aguda/genética; Genes neoplásicos; Mutação; Organização Mundial da Saúde; Neoplasias hematológicas/classificação; Leucemia/classificação

References


